

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066741-0043	SERIAL NO. 10/511,237
	APPLICANT Andreas Block	
	FILING DATE October 12, 2004	GROUP 1632

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code - Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	**1.	BETT et al., "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3," <u>Proc. Natl. Acad. Sci. USA</u> 91:8802-8806 (1994).
	**2.	BLOCK et al., "Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase," <u>Cancer Gene Therapy</u> 7:438-445 (2000).
	**3.	DE WASCH et al., "Detection of residues of tetracycline antibiotics in pork and chicken meat: correlation between results of screening and confirmatory tests," <u>Analyst</u> 123:2737-2741 (1998).
	**4.	GILLESSEN et al., "Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist," <u>European J. Immunol.</u> 25:200-206 (1995).
	**5.	GOSSEN et al., "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," <u>Proc. Natl. Acad. Sci. USA</u> 89(12):5547-51 (1992).
	**6.	GOSSEN et al., "Transcriptional activation by tetracyclines in mammalian cells," <u>Science</u> 268:1766-1769 (1995).
	**7.	GRAHAM, "Transformation of rat cells by DNA of human adenovirus 5," <u>Virology</u> 54:536-539 (1973).
	**8.	HARDING et al., "Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system," <u>Nat. Biotechnol.</u> 16:553-555 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066741-0043	SERIAL NO. 10/511,237
	APPLICANT Andreas Block	
	FILING DATE October 12, 2004	GROUP 1632

	**9.	HARDING et al., "Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors," <u>J. Neurochem.</u> 69:2620-2623 (1997).	
	**10.	HE and ZHOU, et al., "A simplified system for generating recombinant adenoviruses," <u>Proc. Natl. Acad. Sci. USA</u> 95:2509-2514.	
	**11.	KOZARSKY, "Gene therapy: adenovirus vectors," <u>Curr. Opin. Genet. Dev.</u> 3:499-503 (1993).	
	**12.	LIESCHKE et al., "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nat. Biotechnol.</u> 15:35-40 (1997).	
	**13.	LING et al., "Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity," <u>J. Immunol.</u> 154:116-127 (1995).	
	**14.	MATTNER et al., "The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer," <u>European J. Immunol.</u> 23:2202-2208.	
	**15.	NESBITT et al., "A nonradioactive biochemical characterization of membrane proteins using enhanced chemiluminescence," <u>Anal. Biochem.</u> 206:267-272 (1992).	
	**16.	PELLETT et al., "Nucleotide sequence and predicted amino acid sequence of a protein encoded in a small herpes simplex virus DNA fragment capable of trans-inducing alpha genes," <u>Proc. Natl. Acad. Sci. USA</u> 82:5870-5874 (1985).	
	**17.	SCHULTZE et al., "Efficient control of gene expression by single step integration of the tetracycline system in transgenic mice," <u>Nat. Biotechnol.</u> 14:499-503 (1996).	
	**18.	SHERIDAN et al., "Improved high-performance liquid chromatographic determination of doxycycline in serum and urine using solid-phase extraction columns," <u>J. Chromatography</u> 434:253-258 (1988).	
	**19.	STRATHDEE et al., "Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector," <u>Gene</u> 229:21-29 (1999).	

SDO 79315-1.066741.0043

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.